Experimental Neurobiology 2019; 28(6): 679-696
Published online December 31, 2019
© The Korean Society for Brain and Neural Sciences
Kyujin Hwang1,2†, Kwangsoo Jung3†, Il-Sun Kim2, Miri Kim2, Jungho Han3, Joohee Lim3, Jeong Eun Shin3, Jae-Hyung Jang4 and Kook In Park1,2,3*
1Brain Korea 21 Plus Project for Medical Science, Yonsei University College of Medicine, 2Yonsei Biomedical Research Institute, Yonsei University College of Medicine, 3Department of Pediatrics, Severance Children’s Hospital, Yonsei University College of Medicine, Seoul 03722, Korea, 4Department of Chemical and Biomolecular Engineering, Yonsei University, Seoul 03722, Korea
Correspondence to: *To whom correspondence should be addressed.
TEL: 82-10-9091-9231, FAX: 82-2-393-9118
†These authors contributed equally.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License
(http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Spinal cord injury (SCI) causes axonal damage and demyelination, neural cell death, and comprehensive tissue loss, resulting in devastating neurological dysfunction. Neural stem/progenitor cell (NSPCs) transplantation provides therapeutic benefits for neural repair in SCI, and glial cell line-derived neurotrophic factor (GDNF) has been uncovered to have capability of stimulating axonal regeneration and remyelination after SCI. In this study, to evaluate whether GDNF would augment therapeutic effects of NSPCs for SCI, GDNF-encoding or mock adenoviral vector-transduced human NSPCs (GDNF-or Mock-hNSPCs) were transplanted into the injured thoracic spinal cords of rats at 7 days after SCI. Grafted GDNF-hNSPCs showed robust engraftment, long-term survival, an extensive distribution, and increased differentiation into neurons and oligodendroglial cells. Compared with Mock-hNSPC- and vehicle-injected groups, transplantation of GDNF-hNSPCs significantly reduced lesion volume and glial scar formation, promoted neurite outgrowth, axonal regeneration and myelination, increased Schwann cell migration that contributed to the myelin repair, and improved locomotor recovery. In addition, tract tracing demonstrated that transplantation of GDNF-hNSPCs reduced significantly axonal dieback of the dorsal corticospinal tract (dCST), and increased the levels of dCST collaterals, propriospinal neurons (PSNs), and contacts between dCST collaterals and PSNs in the cervical enlargement over that of the controls. Finally grafted GDNF-hNSPCs substantially reversed the increased expression of voltage-gated sodium channels and neuropeptide Y, and elevated expression of GABA in the injured spinal cord, which are involved in the attenuation of neuropathic pain after SCI. These findings suggest that implantation of GDNF-hNSPCs enhances therapeutic efficiency of hNSPCs-based cell therapy for SCI.
Spinal cord injury (SCI) is a devastating neurological disorder that leads to motor, sensory, or autonomic dysfunction, and is associated with high rates of mortality and complications including bladder infection, renal failure, cardiovascular disease, and respiratory dysfunctions. There are approximately 180,000 new cases of SCI worldwide per year caused by traffic accidents, sports injuries, and other traumatic events according to an epidemiologic study . Traumatic SCI causes extensive spinal tissue damage, loss of neural cells, axonal injury, demyelination, and glial scar formation, which adversely impact overall patient outcomes and place financial burdens on healthcare systems. However, there is no standard and efficient management approach for SCI patients [2, 3].
Neural stem/progenitor cells (NSPCs) transplanted into the damaged spinal cord robustly engraft, migrate toward the lesion site, differentiate into all three types of neural lineage cells, integrate into host tissues, provide trophic/anti-inflammatory factors, regenerate lost neural circuits, and remyelinate injured axons, all of which are functionally beneficial following SCI [4–12]. In addition, human fetal brain or spinal cord-derived NSPCs (hNSPCs) implanted into animal models of SCI incorporate into the host neural circuitry and improve locomotor function [13–17]. Recent clinical trials demonstrate that transplantation of hNSPCs is safe and potentially efficacious for treatment of SCI [18–20]. However, implanted NSPCs exhibit poor survival, integration, differentiation, and functional neural connections in the inhospitable environment of the injured central nervous system (CNS) [4, 5, 21, 22]. Thus, the therapeutic efficiency of NSPCs for SCI is insufficient.
Glial cell line-derived neurotrophic factor (GDNF) has developmental, neuroprotective and neurotrophic effects on some types of neurons in the CNS and peripheral nervous system [23, 24]. Administration of GDNF reduces motor neuron death, secondary damage, and white matter atrophy in the spinal cord, increases neuronal survival and the number of spared neuronal fibers, promotes the survival and proliferation of Schwann cells (SCs), and improves motor function post-SCI [25–29]. The methods by which GDNF is delivered to the injured spinal cord vary widely, and include osmotic minipumps, direct injection, GDNF-releasing guidance channels, guidance channels containing SCs and GDNF, injectable GDNF-embedded hydrogels, GDNF-releasing biodegradable polymeric microspheres, hydrogel scaffolds containing GDNF and SCs, and genetically modified GDNF-secreting cells [29, 30]. Recent studies suggest that combinational treatments using many types of genetically modified cells, including SCs, olfactory ensheathing cells, immortalized mouse neural stem cells, fibroblasts, bone marrow-derived mesenchymal stem cells (MSCs), and umbilical cord blood mononuclear cells or MSCs, have varying therapeutic potentials for SCI [29, 30].
We previously reported that human fetal brain-derived primary NSPCs implanted into the injured rat spinal cord robustly engraft, migrate, integrate with host cells, and differentiate into neuronal and glial cells, although most remain immature cells, resulting in improved locomotor recovery. However, a clinical trial in which hNSPC were transplanted into patients with traumatic cervical SCI reported limited neurological benefit . This study investigated the regenerative capabilities of hNSPCs transduced with a GDNF-encoding or mock adenoviral vector (GDNF- and Mock-hNSPCs, respectively) implanted into the injured spinal cord of adult rats and compared their therapeutic efficiencies for future clinical trials involving SCI patients.
Human fetal brain tissue was obtained from a cadaver at 13 weeks of gestation with full parental consent and the approval of the Research Ethics Committee of Yonsei University College of Medicine, Seoul, Korea (Permit No. 4-2003-0078) [18, 31]. All procedures conformed with the guidelines of the National Institutes of Health and the Korean Government. Briefly, hNSPCs isolated from the fetal telencephalon were grown as neurospheres in serum-free DMEM/F12 (Gibco, Grand Island, NY) containing 1% (v/v) penicillin/streptomycin (P/S; Gibco), 1% N-2 Supplement (Gibco), 8 μg/mL heparin (Sigma, St. Louis, MO), 20 ng/mL fibroblast growth factor-2 (R&D Systems, Minneapolis, MN), and 10 ng/mL leukemia inhibitory factor (Sigma). All cultures were maintained in a humidified incubator containing 5% CO2 and air at 37°C. Half of the growth medium was replenished every 3~4 days.
Mock-hNSPCs and GDNF-hNSPCs were seeded into a 24-well plate at a density of 2.5×105 cells/well. After 24 or 72 h, media were collected and cleared by centrifugation at 3000 rpm for 3 min. The levels of human GDNF were measured using a human GDNF DuoSet ELISA Development kit (R&D systems) according to the manufacturer’s instructions.
SH-SY5Y human neuroblastoma cells were plated into a poly-L-lysine-coated 6-well plate containing growth medium (MEM/F12 containing 10% fetal bovine serum and 1% P/S) at a density of 1×105 cells/well and cultured for 24 h. Cells were washed twice and then incubated with conditioned medium (CM) of Mock-hNSPCs (Mock-CM) or GDNF-hNSPCs (GDNF-CM) for 24 h. To quantify neurite length, cells were observed under an Olympus IX71 microscope and analyzed with NeuronJ Software. For immunodepletion, GDNF-CM was pre-incubated with 5 μg/mL anti-GDNF (R&D Systems) or isotype-matched IgG antibody (R&D Systems) for 30 min at 37°C. After 24 h, neurite lengths were measured as described previously . Each data point represents the average of the data of three independent replicates.
All animal experiments were performed under a protocol approved by the Institutional Animal Care and Use Committee of Yonsei University College of Medicine and in accordance with the
Animals were randomly assigned to three groups and injected with 12 μL GDNF-hNSPCs (8.0×104 cells/μL;
Adenovirus-infected cells were plated into 8-well chamber slides (Nunc, Roskilde, Denmark) coated with 10 mg/mL poly-L-lysine (PLL; Sigma) at a density of 8×104 cells/well, and differentiated for 7 days in DMEM/F12 containing 1% P/S and 1% N-2 Supplement. Immunocytochemical analysis of cultured cells was performed as described previously [18, 31, 34]. For immunohistochemical analysis, animals were deeply anesthetized and perfused transcardially with PIPES buffer (pH 7.4; Sigma) containing 4% paraformaldehyde at 9 weeks post-transplantation. The spinal cord was subsequently post-fixed in the perfusing solution overnight at 4°C. Tissues were then cryoprotected in phosphate-buffered saline (PBS) containing 30% sucrose for 24~48 h at 4°C. The T8~T10 segment of the spinal cord was separated and embedded in O.C.T compound medium (Sakura Finetek, Torrance, CA). Coronal or sagittal cryostat sections of the cord (16 μm thick) were stained with the antibodies listed in Table 1, as described previously [18, 31]. For the evaluation of the differentiation patterns of engrafted GDNF- and Mock-hNSPCs in the injured spinal cord, one series of parasagittal sections of the spinal cord of rats injected with Mock- or GDNF-hNSPCs (
The images were acquired using a confocal microscope (LSM700; Carl Zeiss, Oberkochen, Germany) and a BX51 microscope (Olympus, Center Vally, PA). Stereology was conducted using a BX51 microscope and ImageJ software (National Institutes of Health) . Systematic random sampling of the tissue was performed according to stereological principles. Starting sections were chosen at random and every sixth section thereafter was analyzed .
Lesion volume, spared tissue volume, and glial scar area were quantified in parasagittal sections of the spinal cord of rats injected with vehicle, Mock-hNSPCs, or GDNF-hNSPCs (
Three parasagittal sections (
Ten coronal sections (
Parasagittal sections (
Rats were anesthetized as described above and perfused transcardially with cold PBS followed by 2% PIPES buffer containing 2% paraformaldehyde and 2% glutaraldehyde (Merck, Darmstadt, Germany) at 9 weeks post-transplantation. The T8~T10 segment of the spinal cord was separated and post-fixed in the same fixatives overnight at 4°C. Fixed cord tissues were embedded in 3% agarose (Sigma) and axially sectioned into 150 μm-thick slices using a vibratome (Campden Instruments, Loughborough, England). Sections were washed with PBS for 15 min and treated with phosphate buffer containing 1% osmium tetroxide for 2 h. After washing in phosphate buffer, sections were dehydrated in graded ethanol solutions, incubated in propylene oxide (Polysciences, Warrington, PA) for 10 min, and embedded in Epon mixture (Epon® 812; Polysciences). Embedded tissue were sectioned into 80 nm-thick slices using a ultramicrotome (Leica Microsystems, Wetzlar, Germany). The slices were placed on a copper grid (Electron Microscopy Sciences, Hatfield, PA), and stained in uranyl acetate (Polysciences) and lead citrate. Images were acquired using a transmission electron microscope (JEM-1011; JEOL, Peabody, MA). The myelin G-ratio was quantified as the ratio of the axon diameter to the diameter of the axon plus the surrounding myelin sheath. The total number of axons sampled in the vehicle-, Mock-hNSPC-, and GDNF-hNSPC-injected groups (
Six weeks after administration of GDNF-hNSPCs, Mock-hNSPCs, or vehicle (
In the same groups of rats, the retrograde tracer Fluorogold (FG; 1.0 μL of 4% FG dissolved in ddH2O; Abcam, Cambridge, MA) was stereotactically injected under anesthesia with a glass micropipette into the left and right sides of the spinal cord at the L2 level at 8 weeks after administration of GDNF-hNSPCs, Mock-hNSPCs, or vehicle. Rats were sacrificed 1 week later. The spinal cords were removed and divided into five segments (cervical, upper thoracic, injury epicenter, lower thoracic, and lumbar parts), and then post-fixed, cryoprotected, and frozen in O.C.T compound as described above. FG-labeled propriospinal neurons (PSNs) were stained with an anti-FG antibody and DAB. Sections were mounted with Vectashield mounting medium or Permount (Fisher Scientific, Fair Lawn, NJ) . To analyze the formation of contacts between the cervical dCST and PSNs, BDA-labelled CST collateral fibers were visualized in axial spinal cord sections with DAB and ammonium nickel sulfate, and FG-labeled PSNs were stained with an anti-FG antibody and biotinylated secondary antibody, combined with streptavidin-HRP in the ABC (Avidin Biotin Complex) method. The numbers of collaterals sprouting from the main dCST, propriospinal neurons (PSNs), and contacts between dCST collaterals and PSNs were counted in 20 consecutive axial sections of the cervical enlargement of the spinal cord (C3 to C5) at an interval of 150 μm. To control for variation in the tracing efficiency, the number of collaterals from the dCST was divided by the number of main dCSTs in the same sections. The number of contacts between dCST collaterals and PSNs was also counted in the same sections.
At 9 weeks post-transplantation, total RNA was isolated from the T8~T10 segment of the spinal cord in rats injected with GDNF-hNSPCs, Mock-hNSPCs, and vehicle as well as sham-operated controls (
Hindlimb locomotor performance was assessed using the open-field Basso-Beattie-Bresnahan (BBB) scoring system . A rat was placed at the center of a circular open field (diameter: 90 cm, wall height: 7 cm) with a non-slip floor for 5 min. Locomotor activity of the hindlimbs was monitored 1 week after injury and weekly for 9 weeks after transplantation. Each score represents a distinct motor functional state from 0 (complete paralysis) to 21 (normal mobility) based on joint movements, stepping ability, coordination, and trunk stability. Examinations were performed by three observers who were unaware of the treatment received by each rat. All rats with SCI were block-randomized into four experimental groups (Sham, Vehicle, Mock-hNSPCs, and GDNF–hNSPCs;
Hindpaw mechanical allodynia was assessed by measuring the withdrawal response to mechanical stimulation with von Frey filaments (Stoelting, Wood Dale, IL) placed on the mid plantar surface of the hindpaw. Before testing, rats were housed in the test cage above a metal mesh and acclimatized for 30 min. The mechanical threshold of a rat was tested prior to surgery and at 14, 28, 42, and 56 days after transplantation. The 50% withdrawal mechanical threshold was measured using Dixon’s up-and-down method . A series of von Frey filaments (log unit: 3.61, 3.84, 4.08, 4.31, 4.56, 4.74, 4.93 and 5.18) were serially applied to the hindpaw with an interval of 10 s in six applications, beginning with the 4.31 log unit von Frey filament.
All statistical analyses were performed using SPSS version 23 (IBM Corp., Armonk, NY, USA). Two groups were compared by the Student’s
The morphology, survival, and proliferation rate of GDNF-hNSPCs, Mock-hNSPCs, and hNSPCs were similar under proliferation conditions. To determine whether virus infection increased release of GDNF protein under differentiation conditions, we performed immunocytochemistry with an anti-GDNF antibody and quantified the amount of GDNF protein secreted into the media by performing an ELISA. The concentration of GDNF in CM of GDNF-hNSPCs was 13.30±0.28 pg/mL and 22.70±1.12 pg/mL after 1 and 3 days, respectively (
We investigated whether factors secreted by GDNF–hNSPCs stimulated neurite outgrowth of SH-SY5Y neuroblastoma cells. Both GDNF- and Mock-CM significantly enhanced neurite length compared with that in the control group (86.1±3.5 μm vs. 38.3±1.8 μm, p<0.001 and 59.0±2.7 μm vs. 38.3±1.8 μm, p<0.001, respectively; Fig. 1E and 1F). In addition, neurite outgrowth was enhanced more by GDNF-CM than by Mock-CM (p<0.01; Fig. 1E and 1F). To confirm that GDNF secreted by GDNF-hNSPCs directly affects neurite outgrowth of SH-SY5Y cells, an immunodepletion study was performed. Neurite length of SH-SY5Y cells treated with GDNF-CM pre-incubated with an anti-GDNF antibody was significantly shorter than that of SH-SY5Y cells treated with GDNF-CM pre-incubated with isotype-matched IgG (62.4±3.1 μm vs. 81.9±3.4 μm; p<0.05; Fig. 1E and 1F). Therefore, GDNF secreted by GDNF-hNSPCs is directly associated with neurite outgrowth.
Nine weeks after implantation of GDNF-hNSPCs into the injured spinal cord of rats, grafted cells showed robust engraftment, long-term survival, an extensive distribution throughout the injured spinal cord, and integration toward the peri-lesion site (Fig. 1G). The percentages of cells expressing the early neuronal marker Tuj1 and the oligodendroglial progenitor marker Olig2 were significantly higher among grafted GDNF-hNSPCs than among grafted Mock-hNSPCs (TUJ1, 38.4%±3.0% vs. 21.3%±3.7%, p<0.05 and Olig2, 13.5%±1.3% vs. 1.5%±0.3%, p<0.05, respectively; Fig. 1H and 1I). The majority of grafted GDNF- and Mock-hNSPCs expressed nestin and GFAP (nestin, 70.2%±4.5% vs. 80.1%±6.0% and GFAP, 71.5%±2.4% vs. 78.5%±3.3%, respectively) although the percentages of cells expressing these markers tended to be lower among GDNF-hNSPCs than among Mock-hNSPCs. Low percentages of grafted GDNF- and Mock-hNSPCs expressed the astrocyte marker S100β (3.5%±0.9% vs. 5.1%±0.2%, respectively; Fig. 1H and 1I). Grafted GDNF-hNSPCs also expressed GDNF in the injured spinal cord (Fig. 1J). These data demonstrate that GDNF-hNSPCs implanted into the injured spinal cord show robust engraftment, long-term survival, an extensive distribution, and differentiate into all three CNS neural cell types (preferentially neurons and oligodendrocytes), although most remain immature.
When spinal cords were analyzed at 9 weeks post-transplantation, many hNuc+ GDNF- and Mock-hNSPCs had survived and migrated extensively to sites rostral and caudal to the lesion epicenter, including spared tissue surrounding the lesion. In addition, multiple neuronal processes expressing NF extended over engrafted human cells (Fig. 2A). Compared with grafted Mock-hNSPCs, grafted GDNF-hNSPCs markedly promoted neurite extension and induced host axonal sprouting (Fig. 2A). These findings suggest that GDNF is one of the most important factors secreted by implanted GDNF-hNSPCs to promote neurite outgrowth and axonal extension in SCI.
High magnification imaging revealed that many NF+ neuronal processes were co-labeled with an antibody to the mature oligodendrocyte marker myelin basic protein (MBP) (Fig. 2B). To investigate the effect of GDNF-hNSPCs on axonal myelination after SCI, histological analysis was performed with an anti-MBP antibody and LFB at 9 weeks post-implantation. The intensity of MBP staining in engrafted sites and adjacent areas was markedly higher in the GDNF-hNSPC-treated group than in the Mock-hNSPC-treated group (Fig. 2C). Staining with LFB and CV was performed to label myelinated regions in parasagittal sections of the spinal cord. The blue area indicated myelinated axons, whereas the violet area indicated demyelination of axons. The demyelinated volume percentage (relative to the total tissue volume) in injured and adjacent areas was significantly lower in the Mock-hNSPC- and GDNF-hNSPC-treated groups than in the vehicle-treated group (vehicle, 29.4%±1.5% vs. Mock-hNSPCs, 21.3%±1.9%, p<0.05 and vehicle vs. GDNF-hNSPCs, 14.0%±1.4%, p<0.05). Furthermore, the demyelinated volume percentage was significantly lower in the GDNF-hNSPC-treated group than in the Mock-hNSPC-treated group (p<0.05; Fig. 2D and 2E). To investigate the arrangement of oligodendrocyte-remyelinated axons, the G-ratio was measured using electron microscopy images. The lower the G-ratio, the greater is the extent of remyelination. Conversely, a higher G-ratio indicates thinner myelin sheaths and incomplete remyelination. The G-ratio was significantly lower in the Mock-hNSPC- and GDNF-hNSPC-treated groups than in the vehicle-treated group (0.72±0.01 vs. 0.77±0.01, p<0.05 and 0.67±0.01 vs. 0.77±0.01, p<0.05, respectively). In addition, the G-ratio was significantly lower in the GDNF-hNSPC-treated group than in the Mock-hNSPC-treated group (p<0.05; Fig. 2F and 2G). These findings indicate that grafted GDNF-hNSPCs enhance host axonal regeneration and myelination in the injured spinal cord. Moreover, myelin sheaths of regenerated axonal fibers were thicker in the GDNF-hNSPC-treated group than in the vehicle- and Mock-hNSPC-treated groups at the ultrastructural level.
To assess SCs after SCI, we measured the immunostaining density of the SC marker Schwann/2E in the injured spinal cord. The immunostaining density were normalized against that in the vehicle-treated group. The normalized Schwann/2E immunostaining density was significantly higher in the GDNF-hNSPC- and Mock-hNSPC-treated groups than in the vehicle-treated group (165.4%±6.8% and 131.7%±4.0%, p<0.05, respectively). Moreover, it was significantly higher in the GDNF-hNSPC-treated group than in the Mock-hNSPC-treated group (p<0.05; Fig. 2H and 2I). Thus, grafted GDNF-hNSPCs substantially facilitate infiltration of SCs into the injured spinal cord and this contributes to myelin repair.
To examine whether GDNF-hNSPCs implanted into the injured spinal cord protect the dCST, BDA was injected into the sensorimotor cortex at 6 weeks post-transplantation. Texas Redlabeled dorsal corticospinal axonal fibers in tissue adjacent to the lesion epicenter were detected 3 weeks later. The density of BDA-labeled fibers at 6 mm rostral to the lesion epicenter was markedly higher in the GDNF-hNSPC-treated group than in the vehicle-and Mock-hNSPC-treated groups (Fig. 3A). The number of dCST fibers at 4, 5, and 6 mm rostral to the lesion epicenter was higher in the GDNF-hNSPC-treated group than in the Mock-hNSPC- and vehicle-treated groups (p<0.05; Fig. 3B). However, BDA-labeled dCST fibers were not detected caudal to the injury epicenter in any group.
To examine whether GDNF-hNSPCs implanted into the injured spinal cord promote the formation of detour circuits in the same group of rats, the retrograde tracer FG was injected into the spinal cord at the L2 level at 8 weeks after injection of GDNF-hNSPCs, Mock-hNSPCs, or vehicle. At 9 weeks post-injection, the numbers of collaterals sprouting from the main dCST, PSNs, and contacts between collaterals and PSNs were counted in the cervical enlargement of the spinal cord. When the number of collaterals from the dCST was divided by the number of main dCSTs in the same sections, the percentage of collaterals was significantly higher in the GDNF-hNSPC-treated group than in the vehicle-treated group (2.1±0.4% vs. 0.5±0.2%, p<0.05). This value tended to be higher in the Mock-hNSPC-treated group than in the vehicle-treated group; however, this difference was not significant (1.3±0.4% vs. vehicle; Fig. 3C and 3D). The average number of FG-labeled PSNs was significantly higher in the GDNF-hNSPC-treated group than in the vehicle-treated group (4.9±1.0 vs. 0.7±0.4, p<0.05). This value tended to be higher in the Mock-hNSPC-treated group than in the vehicle-treated group; however, this difference was not significant (1.0±0.3 vs. vehicle; Fig. 3C and 3D). Contacts between dCST collaterals and PSNs were observed in the GDNF-hNSPC-treated group, but not in the Mock-hNSPC- and vehicle-treated groups (Fig. 3E and 3F). These results suggest that implantation of GDNF-hNSPCs protects some injured corticospinal fibers and promotes the formation of detour circuits in the injured spinal cord.
To examine the neuroprotective effects of GDNF-hNSPC implantation on the injured spinal cord, we assessed the lesion volume, spared tissue volume, and glia scar formation by performing immunostaining for GFAP at 9 weeks post-transplantation. Lesion volume was significantly smaller in the Mock-hNSPC- and GDNF-hNSPC-treated groups than in the vehicle-treated group (3.1±0.3 mm3 vs. 4.3±0.2 mm3, p<0.05 and 1.6±0.3 mm3 vs. 4.3±0.2 mm3, p<0.001, respectively). Moreover, lesion volume was significantly smaller in the GDNF-hNSPC-treated group than in the Mock-hNSPC-treated group (p<0.05; Fig. 3G and 3H). Spared tissue volume was significantly larger in the GDNF-hNSPC-treated group than in the vehicle-treated group (13.6±1.0 mm3 vs. 9.0±0.7 mm3, p<0.05), but did not differ between the vehicle- and Mock-hNSPC-treated groups (vehicle vs. 10.9±1.0 mm3; Fig. 3G and 3H). In addition, the normalized GFAP immunostaining density was significantly lower in the GDNF-hNSPC- and Mock-hNSPC-treated groups than in the vehicle-treated group (64.8%±3.1%, p<0.001 and 83.2%±1.0%, p<0.05, respectively) and was significantly lower in the GDNF-hNSPC-treated group than in the Mock-hNSPC-treated group (p<0.05; Fig. 3G and 3H). These results suggest that grafted GDNF-hNSPCs significantly reduce tissue damage and glia scar formation in the lesion epicenter and adjacent areas of the injured spinal cord.
We evaluated the capacity of implanted GDNF-hNSPCs to improve hindlimb locomotor function in rats with SCI using the open-field BBB scoring system. BBB scores were around 21 in all sham groups. Prior to transplantation, BBB scores did not differ among the three groups. BBB scores across different time points before and after cell transplantation were significantly different among experimental groups (p=0.000). GDNF-hNSPCs induced significant functional recovery at 1, 2, 3, 4, 5, 6, 7, 8, and 9 weeks post-transplantation compared with the vehicle control (4.2±0.3 vs. 2.9±0.3; 5.4±0.4 vs. 3.8±0.4; 6.4±0.5 vs. 3.9±0.4; 7.2±0.5 vs. 4.5±0.4; 7.4±0.6 vs. 4.2±0.4; 7.4±0.6 vs. 4.4±0.5; 7.7±0.6 vs. 4.5±0.5; 7.8±0.6 vs. 4.6±0.4; and 7.8±0.6 vs. 4.3±0.5, respectively; Fig. 4A). BBB scores were significantly higher in the GDNF-hNSPC-treated group than in the Mock-hNSPC-treated group at 1, 3, 4, 5, 7, 8, and 9 weeks post-transplantation (4.2±0.3 vs. 3.0±0.4; 6.4±0.5 vs. 4.5±0.5; 7.2±0.5 vs. 5.0±0.5; 7.4±0.6 vs. 5.4±0.6; 7.7±0.6 vs. 5.8±0.6; 7.8± 0.6 vs. 5.7±0.6; and 7.8±0.6 vs. 5.8±0.5, respectively; Fig. 4A). BBB scores tended to be higher in the Mock-hNSPC-treated group than in the vehicle-treated group; however, this difference was not statistically significant. These data demonstrate that implantation of GDNF-hNSPCs improves hindlimb locomotor performance of rats with SCI without causing abnormal neurological behaviors.
We also assessed the effects of GDNF-hNSPC implantation on development of neuropathic pain after SCI by evaluating mechanical allodynia via the von Frey test. The mechanical withdrawal threshold across different time points before and after cell transplantation were significantly different among experimental groups (p=0.000). The mechanical withdrawal threshold in the vehicle-treated group was much lower at 2, 4, 6, and 8 weeks post-injection than prior to injury (4.4±0.9, 2.6±0.4, 2.6±0.3, and 1.9±0.4, respectively; Fig. 4B). The mechanical withdrawal threshold was significantly higher in the Mock-hNSPC-treated group than in the vehicle- treated group at 4, 6, and 8 weeks post-transplantation (5.7±1.2 vs. vehicle; 6.8±1.4 vs. vehicle; and 6.7±1.1 vs. vehicle, respectively; Fig. 4B). The mechanical withdrawal threshold was significantly higher in the GDNF-hNSPC-treated group than in the vehicle-treated group at 2, 4, 6, and 8 weeks post-transplantation (9.2±1.0 vs. vehicle,; 10.1±0.8 vs. vehicle; 10.9±0.9 vs. vehicle; and 10.3±1.1 vs. vehicle, respectively). Furthermore, the mechanical withdrawal threshold was significantly higher in the GDNF-hNSPC-treated group than in the Mock-hNSPC-treated group at 4, 6, and 8 weeks post-transplantation (Fig. 4B). In the sham group, the mechanical withdrawal threshold was 15±0.2. Hence, transplantation of GDNF-hNSPCs efficiently attenuates mechanical allodynia after SCI.
To investigate the effect of GDNF-hNSPC implantation on expression of voltage-gate sodium channels (Nav) linked with neuropathic pain in SCI, we analyzed Nav1.3 and Nav1.9 expression in the T8~T10 segment of the spinal cord at 9 weeks post-transplantation by performing qRT-PCR. Expression of Nav1.3 (1.61±0.09-fold, p<0.05) and Nav1.7 (2.25±0.29-fold, p<0.05) was higher in the vehicle-treated group than in the sham-operated control. Expression of Nav1.3 (1.45±0.07-fold) and Nav1.7 (1.86±0.20-fold) tended to be lower in the Mock-hNSPC-treated group than in the vehicle-treated group; however, these differences were not significant. However, expression of Nav1.3 (0.95±0.19-fold, p<0.05) and Nav1.7 (1.15±0.15-fold, p<0.05) in the GDNF-hNSPC-treated group was comparable with that in the sham-operated control and was significantly lower than that in the vehicle-treated group (Fig. 4C). In addition, expression of Nav1.3 was significantly lower in the GDNF-hNSPC-treated group than in the Mock-hNSPC-treated group.
The normalized NPY immunostaining density at lamina I of the dorsal horn in the T8 segment of the spinal cord was significantly higher at 9 weeks after vehicle injection (129.85%±4.89%, p<0.05) than in the sham-operated control. However, the normalized NPY immunostaining density in the GDNF-hNSPC-treated group (106.28%±3.14%, p<0.05) was similar to that in the sham-operated control and was significantly lower than that in the vehicle-treated group. The normalized NPY immunostaining density tended to be lower in the Mock-hNSPC-treated group than in the vehicle-treated group; however, this difference was not significant (115.69%±1.37%; Fig. 4D and 4E).
The normalized GABA immunostaining density in the T8~T10 segment of the spinal cord at 9 weeks post-transplantation was significantly higher in the GDNF-hNSPC-treated group (198.36±24.81%) than in the vehicle-treated group and tended to be higher in the Mock-hNSPC-treated group than in the vehicle-treated group; however, this difference was not significant (131.04±9.48%; Fig. 4F and 4G). Histochemical analysis confirmed that many implanted GDNF-hNSPCs expressed GABA and thus gave rise to GABAergic cells in the injured spinal cord (Fig. 4H). These results suggest that reversion of Nav and NPY upregulation and increased GABA expression upon implantation of GDNF-hNSPCs alleviates mechanical allodynia after SCI.
SCI is a devastating, life-changing disorder with many serious consequences and no known effective treatment. Cell transplantation has emerged as a promising therapeutic method to enhance repair following SCI. Various types of cells, including SCs, oligodendrocyte precursor cells, NSPCs, MSCs, and olfactory ensheathing cells, have been evaluated in terms of their capacity to regenerate the injured spinal cord upon transplantation . Although cell transplantation has been intensely studied, it remains unclear how implanted cells yield therapeutic effects in SCI. We previously reported that human fetal brain-derived primary NSPCs implanted into the injured spinal cord of adult rats exhibit robust engraftment, extensive migration, long-term survival, and differentiation into neuronal and glial cells, although most remain immature, resulting in modest improvement of motosensory function [18, 44]. Following implantation, hNSPCs are suggested to have functional benefits for SCI via a variety of mechanisms, including neuroprotection, neural plasticity, immunomodulation, angiogenesis, neurite outgrowth, axonal extension, and cellular replacement [18, 44]. Based on these preliminary data, several early-phase clinical trials were performed. These demonstrated that transplantation of human fetal brain- or spinal cord-derived NSPCs is generally feasible and safe, and yields minimal or modest neurological improvement; however, the long-term efficacy and safety remain unproven [18–20]. The patterns of cellular responses to SCI are extremely heterogeneous and complex; therefore, simply delivering specific neural cell types into the injured spinal cord via cell or stem cell therapy is ineffective . Thus, the therapeutic efficiency of hNSPCs for SCI is insufficient and there is no cure for this condition.
One possible treatment strategy for SCI is to prevent neurode-generation and stimulate regeneration using GDNF. GDNF has extensive effects on repair after SCI and these have been broadly examined. To improve the therapeutic efficiency of GDNF, future research should focus on enhanced delivery methods using biomaterials, nanoparticles, viral vectors, or genetically modified cells to secrete both GDNF and other trophic factors over time [29, 30, 44]. Previous research indicated that direct in vivo GDNF gene therapy using viral vectors or plasmid DNA protects motor neurons and promotes functional recovery after SCI . Adenovirus-or herpes simplex virus-mediated GDNF gene therapy reduces motor neuron injury, preserves neuronal fibers, and improves locomotor function in rats with SCI [46–49]. However, in vivo gene therapy using viral vectors is associated with several complications, including non-specific targeting and gene expression, gene silencing, and an immune response to the vector .
Ex vivo gene therapy allows the genetically engineered cell product to be characterized in vitro prior to administration and does not involve direct exposure of the patient to the viral vector. In addition, grafted genetically modified cells not only replace the neural cell types lost to injury and support diseased neurons and/or dysfunctional glia, but also produce additional endogenous trophic and immunomodulatory molecules that augment their therapeutic potential. Various cell types have been used in combined cell and gene therapeutic approaches to provide GDNF to the injured spinal cord [29, 30]. GDNF-overexpressing SCs implanted into the injured spinal cord modulate astrocytic glial scars, promote propriospinal axonal regeneration and synapse formation, and improve functional recovery . Implantation of hydrogel scaffolds containing GDNF-overexpressing SCs into the transected spinal cord also promotes axonal growth and axon myelination . Grafted genetically modified GDNF-secreting MSCs or umbilical cord blood-derived mononuclear cells induce functional recovery and tissue sparing, and increase myelination after SCI [45, 53]. These studies suggest that ex vivo GDNF gene therapy with multiple cell types has beneficial effects for spinal cord repair. This may be because the complicated and dynamic milieu resulting from SCI seems to require combinational treatment approaches. However, while immortalized mouse NSCs constitutively secrete GDNF together with other neurotrophic factors and promote axonal growth after SCI, implantation of mouse NSCs genetically engineered to overexpress GDNF into the injured spinal cord does not improve locomotor function and significant forelimb thermal and mechanical allodynia because these cells exclusively undergo astrocytic differentiation [9, 54].
Human fetal cortex-derived primary NSPCs genetically modified to stably express GDNF using a lentivirus survive, migrate, secrete GDNF, and protect degenerating neurons [55, 56]. These cells are safe and non-tumorigenic, and are currently being used in a phase 1/2a clinical trial incorporating cell and gene therapy to protect motor neurons in patients with amyotrophic lateral sclerosis . Therefore, in this study, we evaluated the regenerative ability of human fetal brain-derived NSPCs engineered to secrete GDNF via infection of an adenovirus in rats with SCI and compared their therapeutic efficiency with that of Mock-hNSPCs for a future clinical trial. Ex vivo transduction of hNSPCs with a GDNF-encoding adenoviral vector leads to effective expression of GDNF. In addition, GDNF-hNSPCs might secrete multiple other active factors that enhance neuronal survival and neuroplasticity, reduce secondary damage, and stimulate the endogenous repair system via inducing favorable changes in the environmental milieu of the damaged spinal cord [31, 44]. In the present study, although GDNF-hNSPCs were implanted into the injured spinal cord at 7 days after SCI during the subacute stage, they showed robust engraftment, long-term survival, an extensive distribution, and increased differentiation into neurons and oligodendroglial cells in the lesion and adjacent sites. Therefore, grafted cell-derived GDNF and other therapeutic molecules diffuse beyond the engraftment sites over a long period, which may contribute to extensive neuroprotection, decreased lesion volume, promotion of neurite outgrowth and axonal extension, increased SC migration and myelination, modulation of astrocytic glial scars, and improved motosensory function post-SCI.
Compared with grafted Mock-hNSPCs, grafted GDNF-hNSPCs showed increased differentiation into neurons and oligodendrocytes, although most remained immature, and these cells might be able to reconstitute the injured spinal cord. However, further studies are needed to electrophysiologically confirm the functional neural connections and efficient axonal connectivity between host and donor-derived neurons.
SCI induces neuronal death at the injury site and extensive axonal dieback of the dCST, which is pivotal for voluntary movement . Neuroprotection of damaged axons and increased axonal plasticity are important for locomotor recovery. hNSPCs produce various neurotrophic factors that support neuroprotection and neurite outgrowth . In addition, GDNF promotes axonal plasticity in CSTs and newly formed PSNs after SCI [59, 60]. After SCI, transected mid-thoracic CST axons sprouted into the cervical gray matter where they contact descending ‘long’ and ‘short’ PSNs. Long PSNs originate in the cervical enlargement (C3~C5), travel in the ventral and lateral funiculi, and terminate in the ventral horn of the lumbosacral enlargement bridging spinal levels above and below the lesion. In contrast, short PSNs connect the upper (C3~C4) and lower (C6~T1) cervical cord, not bridging spinal levels above and below the lesion. Transected CST axons sprout into short and long PSNs in the cervical enlargement equally, but sprouts that contacted long PSNs are maintained, thereby creating a new intraspinal circuit (detour circuit) . In this study, transplanted GDNF-hNSPCs induced host axonal regrowth, protected the dCST, and increased the number of PSNs and contacts between dCST collaterals and PSNs in the cervical enlargement promoting the formation of detour circuits in the injured spinal cord.
In terms of motor function recovery after SCI, a previous study reported that grafted GDNF-secreting olfactory ensheathing cells and GDNF-secreting SCs increased the BBB score by almost 8 and about 5 compared with controls, respectively . In this study, the BBB score was approximately 3.5 higher in the group transplanted with GDNF-hNSPCs during the subacute stage after severe contusive SCI than in the control group at 9 weeks post-transplantation. However, it is difficult to directly compare the improvements of BBB scores between studies because the type of SCI (contusion, hemisection, and complete transection), level of injury, concentration of secreted GDNF, GDNF delivery method, and timing of transplantation after SCI differ.
In animal models, GDNF exerts potent analgesic effects on neuropathic pain, although the underlying mechanisms have not been completely elucidated . GDNF reverses nerve injury-induced changes, including expression of the P2X3 purinoreceptor, sodium channels, neuropeptides, and regulator of G-protein signaling protein 4, as well as IB4 binding, in dorsal root ganglion neurons . However, effective GDNF delivery methods to relieve neuropathic pain are still under investigation. In addition, GDNF-hNSPCs were more differentiated into GABA+ neurons than Mock-hNSPCs. Thus, the increased supply of donor-derived GABAergic neurons may be able to restore the inhibitory function to the spinal cord dorsal horn to decrease the hyperexcitability that develops in dorsal horn projection neurons [62–65]. The increased GABA production is a potential mechanism of behavioral improvement in the allodynic rat after SCI. Furthermore, GABA as well as other trophic factors including GDNF secreted by transplanted cells would protect endogenous spinal cord inhibitory interneurons after SCI. Thus, not only Mock-hNSPCs but also GDNF-hNSPCs implanted into SCI would attenuate neuropathic pain. Taken together, grafted GDNF-hNSPCs reversed the upregulation of Nav and NPY, increased GABA expression, and a rare differentiation of donor-derived cells into astrocytes, which contributed to marked alleviation of mechanical allodynia after SCI.
Demyelination is a major hurdle for recovery after SCI. Although resident OPCs can replace damaged oligodendrocytes, the inhibitory milieu of the injured spinal cord prevents mature myelination . Transplantation of OPCs or SCs is effective for SCI recovery [67, 68]. However, OPCs and SCs are difficult to isolate and this limits their use. In this study, grafted GDNF-hNSPCs showed increased differentiation into oligodendrocytes and enhanced migration of SCs toward the injured spinal cord. SCs migrate to lesion sites in the spinal cord, participate in remyelination in these areas, and support axonal growth . GDNF stimulates migration of SCs and enhances myelination through the NCAM signaling pathways that regulate myelin formation . Thus, the combinational approach using hNSPCs and GDNF induced robust remyelination in damaged areas by host SCs and donor-derived oligodendrocytes after SCI.
In summary, transplantation of GDNF-hNSPCs is a promising combinational treatment approach to enhance repair of the injured spinal cord. The GDNF gene was efficiently transduced using an adenoviral vector, and GDNF-hNSPCs expressed GDNF for a long duration both in vitro and in vivo. GDNF-hNSPCs implanted into the injured spinal cord showed robust engraftment, long-term survival, an extensive distribution, and increased differentiation into neurons and oligodendrocytes in the lesion and adjacent areas. This resulted in extensive neuroprotection, decreased lesion volume, promotion of neurite outgrowth and axonal extension, increased SC migration and myelination, modulation of astrocytic glial scars, and improved functional recovery post-SCI. These findings support the investigation of GDNF-hNSPCs in a clinical trial for SCI.
This study was supported by grants from Korean Health Technology R&D Project (HI16C1089) and the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) (No. NRF-2019M3A9H1032791).
Table 1. Lists of antibodies used for immunostaining and primers used for qPCR.
|SCN3A (Nav1.3)||158||F: 5′-AACGAAAGACGATCAAGACC-3′|
|SCN9A (Nav1.7)||163||F: 5′-GGGAACTTGATCTTTACAGGG-3′|
|18S rRNA||77||F: 5′-TTGATTAAGTCCCTGCCCTTT-3′|